Dermatology

Adapalene with benzoyl peroxide

Brand: Epiduo®

PBAC's latest decision on Adapalene with benzoyl peroxide: Recommended with restriction (2010). Considered for acute treatment, in combination with an oral antibiotic, of severe acne vulgaris; maintenance treatment of severe acne vulgaris.

PBAC outcome

Recommended with restriction

Restricted benefit

ICER (AUD/QALY)

$75k/QALY

Range: $45k/QALY–$75k/QALY

Submissions

first 2010

Submissions

2010 → 2010

Eligible population

patients with severe acne vulgaris

Therapy area: Dermatology
Line of therapy: Not applicable
Evidence base: RCT
Primary endpoint: OS | PFS | DFS | ORR | QoL | Surrogate
Key trials: ACCESS-1, ACCESS-2, Gollnick 2009, Stein Gold 2009, Thiboutot 2007
Comparator: placebo
Economic model: CUA
ICER note: Base-case ICER was $15,000–$45,000/QALY; sensitivity analyses increased ICER to $45,000–$75,000/QALY using lower bound of 95% CI for odds ratio and smaller utility gain.

Open on full dashboard →